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Neuropathic orofacial pain – diagnostic  
and therapeutic challenges
Abstract
Chronic neuropathic orofacial pain (OFP) is the leading symptom for a 
wide range of conditions. It can exist independently of any addition signs, 
symptoms and radiological or laboratory abnormalities. In addition to 
physical suffering, OFP causes emotional, psychological and social distur-
bances and thus significantly influences the quality of life of those affected. 
Several key factors make OFP a complex diagnostic and therapeutic chal-
lenge. These include a lack of diagnostic criteria that are both validated and 
readily applicable in clinical settings and a lack of sufficient education about 
pain in undergraduate medical training programs. There is also a need to 
develop more analgesic therapies offering improved efficacy and side effect 
profiles. Finally, the provision of analgesic therapies by health insurance 
programs need to be harmonized with the most current evidence-based treat-
ment protocols. In addition to offering recommendations in these areas, this 
paper provides an overview of the most common clinical forms of nonodon-
togenic OFP, epidemiological data, and current diagnostic and therapeutic 
options.
INTRODUCTION
Pain is one of the most unpleasant aspects of many diseases. To under-score the importance of pain as a global health problem, the Interna-
tional Association for the Study of Pain (IASP) launched its first “Global 
Year Against Pain,” in 2004 with the slogan; Pain management should be 
a human right. Each IASP annual campaign is dedicated to the study of 
pain arising from particular conditions or etiologies. For example, 2013 
marked the year against chronic pain, whereas orofacial pain was the 
focus in 2014, which was followed by a year against neuropathic pain in 
2015 (1). Such campaigns help raise awareness for the many ways in which 
various types of pain effect health, ranging from a vital warning sign to 
a debilitating condition. Acute pain, which signals the occurrence of in-
jury or disease, provides an important protective function. Conversely, 
chronic pain provides no real or potential benefits, resulting only in un-
necessary suffering. This is particularly true of neuropathic pain, an im-
portant component of numerous medical conditions (2). Whatever its 
origin, pain is recognized globally as one of the primary reasons for seek-
ing medical attention. The pain suffered by individuals creates not only 
personal but also societal costs. Communities are burdened with both 
the direct costs of healthcare utilization and the indirect costs of reduced 
worker productivity and increased absenteeism due to pain. 
One of the most significant sources of pain in the human body is the 
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The orofacial region also has great psychological signifi-
cance as the center for chewing, swallowing, speech pro-
duction, communication and personal expression (4). 
Therefore, chronic pain is associated with additional emo-
tional, psychological and social disturbances when located 
in the orofacial region. These changes significantly affect 
the quality of life of those living with chronic orofacial pain 
(OFP) (5). The global prevalence of orofacial pain is esti-
mated at 17–26%, with 7–11% of patients experiencing 
chronic OFP (6). It is not known what share of this per-
centage is attributable to neuropathic pain, an important 
causative factor in many OFP conditions. The prevalence 
of orofacial and chronic pain can reasonably be expected 
to increase as demographics shift toward longer life expec-
tancies. An aging population includes an increased number 
of patients living with chronic and painful conditions such 
as diabetes and cancer. Aging also results in increased ex-
posure to therapeutic methods for these and other condi-
tions that can result in neuropathic pain. Such an increas-
ing potential for chronic and orofacial pain creates the need 
to consider a range of likely consequences, not least of 
which is the impact on quality of life (6, 7). 
The causes and mechanisms of chronic pain are not 
entirely clear, although risk and precipitating factors have 
been identified for the majority of conditions. A large 
body of evidence shows that pain is often inadequately 
treated. Over time, continuous pain symptoms alter neu-
roplasticity and may cause hyperexcitability, changes that 
lead to the development of chronic pain (5). Thus, un-
abated neuropathic pain can become a neurological dis-
order or dysfunction of the central nervous system (CNS), 
in much the same way as epilepsy or Parkinson’s disease. 
These changes to the CNS pain signaling pathways hinder 
the effectiveness of therapies aimed at alleviating the 
symptoms of chronic pain.
Nonodontogenic neuropathic  
orofacial pain
A diagnosis of nonodontogenic neuropathic orofacial 
pain can only be made after eliminating the teeth as the 
potential source of pain. Odontogenic OFP arises from 
tooth damage or decay and is often localized to the oral 
cavity. It can also occur in the region of the face that is 
above the neck, in front of the ears,  and below the orbi-
tomeatal line. If dental caries, poor fillings, trauma, and 
dental fractures have all been eliminated as the source of 
pain, OFP is considered unrelated to teeth and is therefore 
referred to as nonodontogenic. Additional findings related 
to the distribution and timing of pain may help confirm 
its origin. Nonodontogenic pain is often treatment resis-
tant, even with the use of local anesthetics and is prone to 
developing into a chronic condition (8). Additionally, pain 
that is bilateral or simultaneously encompasses multiple 
teeth is likely to be of a nonodontogenic origin (9). 
Nonodontogenic neuropathic OFP shares many of the 
characteristic features recognized in other forms of neu-
ropathy. Neuropathic pain arises from peripheral and 
central changes in neuronal function that are perceived as 
persistent pain and sensory abnormalities. Permanent loss 
or injury of primary afferent fibers, a process referred to 
as deafferentation, results in peripheral neuropathic pain. 
Central neuropathic pain, however, arises from direct 
damage to the structure of the central nervous system (10). 
The timing and duration of symptoms are characteristic 
of neuropathic pain, which can be both episodic (or par-
oxysmal) and continuous. While some patients experience 
complete relief from pain symptoms between episodes, 
others can experience paroxysms of pain as an acute exac-
erbation of an otherwise continuous pain syndrome (4). 
While some causes of OFP may be difficult to discern, a 
careful history including the duration and nature of symp-
toms can pinpoint a likely etiology. For example, pain 
described as continuous and burning is typical of neuritis 
and post-traumatic neuropathy. Neuropathy most often 
manifests as repeated, episodic attacks of short stabbing 
or shooting pain. The onset of these episodes can be either 
spontaneous (or stimulus independent) or provoked by 
stimuli. Pain is intensified by the stimulation of trigger-
points or individual muscles. Pain can also be increased 
by emotional stress, physical activity, changes in the posi-
tion of the head and so on. Neuropathic pain is often 
accompanied by additional sensory signs and symptoms 
such as allodynia, pain provoked by a stimulus (as a light 
touch of the skin) which would not normally provoke 
pain. Thermal and mechanical stimuli are the types most 
often associated with provoking allodynia. Hyperalgesia, 
an increased sensitivity to painful stimuli, is another char-
acteristic positive sign. Negative signs, such as hypoalgesia 
and hypoesthesia, can also indicate a neuropathic etiology. 
While many of these signs can be elucidated from patient 
history, the full range of sensory changes experience by an 
individual patient is best assessed using quantitative sen-
sory testing. This non-invasive method relies on the selec-
tive response of specific types of nerve fibers to particular 
stimuli. Given that A-beta fibers are selectively stimulated 
by electricity, A-delta fibers respond to cold or punctate 
mechanical stimuli and C-fibers are stimulated by heat, 
these types of stimuli are applied externally to selectively 
stimulate and record a response from each type of nerve 
fiber. The area from which neuropathic pain and sensory 
changes are elicited represents the receptive field of a par-
ticular nerve, allowing identification of the involved nerve 
or nerve root. Pain in the head and neck is mediated by 
the upper cervical spinal roots, the intermediate, glosso-
pharingeal and vagus nerves, along with sensory fibers 
from the trigeminal nerve (11). 
Trigeminal neuralgia
The most common orofacial clinical entity involving 
underlying neuropathic pain is trigeminal neuralgia 
(TN). Trigeminal neuralgia; also known as tic doulou-
reux, Fothergill disease and suicide disease; is estimated to 
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affect 4–13 people per 100,000 population (11–13). It 
occurs at a rate of about 15,000 new cases per year in the 
US (14). TN can occur at any age, including childhood, 
but the incidence generally increases with age. Idiopathic 
cases are the most common after the age of 50 (15). Con-
sidered a natural consequence of their longer life expec-
tancies, women are about 1.5 times more likely to experi-
ence TN (14). Although the disease is more common in 
some families, 80–90% of TN is sporadic (16) and at-
tributable to aberrant loop arteries or veins compressing 
the trigeminal root (17–19). This frequent etiology makes 
trigeminal neuralgia due to vascular compression (10) 
considered “classical” idiopathic trigeminal neuralgia. 
Secondary TN arises from compression by other struc-
tures, such as an acoustic neuroma, meningioma, epider-
moid cyst, aneurysm or AV malformation (10, 20–26). 
Although all three branches of the trigeminal nerve may 
be involved, TN is usually limited to one or two branch-
es. The second and third trigeminal branches are those 
most commonly affected by TN. The first branch of the 
trigeminal nerve is affected in only about 5% of TN 
cases, usually due to herpes zoster infection. The pain of 
trigeminal neuralgia is usually unilateral, sudden, severe, 
and sometimes described as lightning–like. Pain may be 
bilateral, but both sides are not usually affected at the 
same time (14). TN is often accompanied by paresthesias, 
such as burning and shock-like sensations. Pain and par-
esthesia symptoms can be provoked by chewing, talking, 
brushing teeth, cold air, laughing, light touch, smiling or 
any other stimulation of trigger-points around the nose 
and mouth. As is typical of allodynia, the pain induced 
by trigger-points is usually disproportionate to the stimu-
lus, such that a mild stimulus causes severe pain. Notably, 
injection of local anesthetic at trigger-points is usually 
effective in providing pain relief. The pain of trigeminal 
neuralgia typically occurs as episodic attacks ranging in 
duration from a few seconds to several minutes. Whereas 
the pain typically subsides completely between episodes, 
some patients with long-standing TN experience pain 
continuously between paroxysms. Although the course of 
the disease is unpredictable, symptomatic periods of fre-
quent TN paroxysms generally occur over the course of 
weeks or months, followed by periods of remission. The 
course of the disease for some patients tends toward un-
remitting pain while others experience a decrease in fre-
quency and intensity of TN symptoms. Patients with 
trigeminal neuralgia are generally able to sleep through 
the night without suffering paroxysms of pain. 
The diagnostic criteria for classical trigeminal neural-
gia described in the Third International Classification of 
Headache Disorders (ICHD-3) of the International 
Headache Society (IHS) (10) are based on the timing, 
characteristics and distribution of OFP. Classic TN pres-
ents as paroxysmal pain that is intense, sharp, superficial, 
stabbing, or was precipitated from stimuli at trigger-
points and lasts up to two minutes. The pain involves one 
or more branches of the trigeminal nerve and is not as-
sociated with any other disease. In addition, attacks are 
stereotyped in individual patients who have no clinically 
evident neurological deficit. 
The ICHD-3 diagnostic criteria for secondary (or 
symptomatic) trigeminal neuralgia require that anything 
other than vascular compression causes the spectrum of 
symptoms associated with TN. One distinctive clinical 
feature of the secondary form is that it lacks a refractory 
period after paroxysms (10). Potential causes of secondary 
TN include acute herpes zoster, postherpetic neuralgia, 
trauma, multiple sclerosis plaques, and other non-vascular 
compressive lesions. Post-traumatic trigeminal neuropa-
thy, or anesthesia dolorosa, is an important cause of sec-
ondary TN that is defined by the ICHD-3 (10) as one-
sided pain of the face or oral cavity in a patient with a 
history of verified mechanical, chemical, thermal or radi-
ation-induced trauma in the same area of  the trigeminal 
nerve associate with symptoms. The pain must appear 
within three to six months after the traumatic event, and 
is not better characterized by another ICHD-3 diagnosis. 
The pain of post-traumatic TN must also be associated 
with clinically apparent positive or negative signs of tri-
geminal nerve dysfunction. Positive signs such as hyper-
algesia and allodynia may coincide with negative signs 
such as hypoesthesia and hypoalgesia. The clinical finding 
of pain in a facial area where the sensation is either miss-
ing or impaired is characteristic of anesthesia dolorosa. 
Patients can find this mix of positive and negative symp-
toms difficult to explain, making a careful clinical his-
tory especially important in identifying causes of central 
pain such as post-traumatic TN.
While the precise mechanism remains to be fully eluci-
dated, the symptoms associated with trigeminal neuralgia 
are likely due to demyelination in the area of  compression 
or damage (27, 28). Demyelination also occurs in multiple 
sclerosis and other structural lesions of the brain stem, mak-
ing these an important part of the differential diagnosis 
(29–32). Demyelinated areas can generate ectopic impuls-
es that contribute to abnormal nerve conduction (17). Such 
alteration of afferent inputs can disinhibit pain pathways 
in the spinal trigeminal core. Evidence supporting involve-
ment of central pain mechanisms includes the occurrence 
of a refractory period after triggered episodes of pain (29). 
During the refractory period, which usually lasts a few 
minutes, a paroxysm of pain is not possible. The complex 
mechanisms involved in the development and presentation 
of trigeminal neuralgia require a range of specialists includ-
ing dentists and neurologists be included in a multidisci-
plinary approach to its diagnosis and treatment. 
Herpes zoster and postherpetic 
neuralgia
Herpes zoster may cause pain with neuropathic char-
acteristics in the area innervated by one of the facial 
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nerves. Systemic and topical analgesics may help but are 
usually insufficient for providing complete pain relief. The 
onset of pain from herpes zoster often precedes the occur-
rence of the vesicular rash and can persist even months 
after the lesions are no longer visible. The diagnosis of 
OFP due to herpes zoster is often difficult, particularly 
before the appearance of the characteristic rash. The pri-
mary factor confounding a clear diagnosis is that herpes 
zoster can mimic dental pain. Reliable laboratory tests for 
the unambiguous diagnosis of herpes zoster OFP have not 
yet been developed. Early diagnosis and treatment may 
help prevent the development of postherpetic neuralgia 
(PHN), a condition in which pain endures at least one 
month after the herpes zoster rash has healed. The pain is 
usually a continuation of that experienced before and dur-
ing the acute herpes zoster skin eruption. While it usu-
ally lasts up to six months, PHN can continue for years 
after the rash has healed. 
Atypical odontalgia
Atypical odontalgia is characterized by constant pain 
after removal of a tooth, tooth apex, or dental pulp. Also 
known as idiopathic, or phantom, toothache, this condi-
tion can also be caused by facial trauma. Studies have 
shown that atypical odontalgia appears in 3–6% of pa-
tients after endodontic treatment. In atypical odontalgia, 
a throbbing ache is experienced in the area of a tooth or 
alveolar process over prolonged periods. The sensation 
may be intermittent or constant, and persists despite a 
lack of clinical and radiographic evidence that would in-
dicate a disorder related to the teeth. Patients may have 
difficulty localizing the pain, which is usually more in-
tense on the side where the trauma or dental procedure 
occurred. The pain may spread into adjacent areas unilat-
erally and bilaterally, with the teeth most frequently af-
fected being the upper premolars and molars. Local an-
esthesia can, but does not necessarily, alleviate the pain. 
Unfortunately, the symptoms of atypical odontalgia are 
often untreated as they are mistaken for a normal re-
sponse to the treatment or trauma that precipitated this 
OFP condition.
Glossopharyngeal neuralgia
Glossopharyngeal neuralgia is an infrequent disorder 
that is likely due to compression of the glossopharyngeal 
or upper portions of the vagus nerve. Damage to these 
nerves is suggested by asymmetry in the movement of the 
soft palate and uvula or the absence of the emetic reflex 
(33).  Glossopharyngeal neuralgia manifests as paroxys-
mal pain in the area innervated by the  9th and 10th cra-
nial nerves and is most often experienced as pain in the 
throat, particularly when chewing and swallowing (10, 
34). The pain, which is usually unilateral, can encompass 
the pharynx, base of the tongue, and the area inferior to 
the angle of the mandible and ear. The pain may encom-
pass the receptive field of the auricular and pharyngeal 
branches of the vagus nerve. Bilateral involvement is pos-
sible and occurs in about 12% of patients (35). The ca-
rotid arteries should be examined for pathological chang-
es such as arterial dissection, before considering other 
potential sources of pain in this region. If the teeth, ears 
and carotid arteries have been eliminated as the source of 
pain, glossopharyngeal neuralgia should be considered in 
the differential diagnosis. Trigeminal neuralgia, which is 
70 to 100 times more common than glossopharyngeal 
neuralgia, can occur as a comorbid condition .  
The pain of glossopharingeal neuralgia is usually pro-
jected from the oropharynx to the ear. It is usually parox-
ysmal and intense, but can be superimposed on a con-
stant, less severe pain. Attacks may occur several times 
per day and may even arouse the patient from sleep. The 
ICHD-3 diagnostic criteria for glossopharyngeal neural-
gia requires at least three attacks of unilateral pain, in the 
base of the tongue, tonsillar fossa, pharynx, below the 
angle of the mandible or ear in patients without evident 
neurological deficit (10). Glossopharyngeal neuralgia oc-
curs in paroxysmal attacks of strong, sharp, stabbing, or 
throbbing pain that lasts up to two minutes. Movements 
such as swallowing, coughing, talking or yawning can 
induce paroxysms of pain. Such findings, if not better 
characterized another ICHD-3 diagnosis, confirm a di-
agnosis of glossopharyngeal neuralgia. As with trigeminal 
neuralgia, glossopharyngeal neuralgia exists as either a 
primary or a secondary OFP condition. Secondary glos-
sopharyngeal neuralgia can be caused by demyelinating 
lesions, tumors in the cerebellopontine angle, peritonsillar 
abscess, aneurysm of the carotid artery, Eagle’s syndrome, 
(36–39) and vascular compression of the vertebral artery 
or rear lower cerebellar artery. Similar to trigeminal neu-
ralgia, episodes of glossopharyngeal neuralgia can last for 
weeks or months, punctuating long periods of remission. 
A key diagnostic feature, glossopharyngeal neuralgia is 
the only cranial neuralgia in which painful afferent im-
pulses can precipitate a cardioinhibitory reflex causing 
vagal bradycardia, asystole and syncope (34, 40). This 
symptom must be distinguished from cardiac pain that 
radiates to the orofacial area, such as may occur with 
sickle cell anemia and some neoplasms. It should be not-
ed that pain resembling that of glossopharyngeal neural-
gia can also be of traumatic, postoperative, and psycho-
genic origin. Also included in the differential diagnosis of 
glossopharyngeal neuralgia are several rare disorders such 
as neuralgia of the intermediate nerve, occipital neuralgia, 
optic neuritis, headache due to ipsilateral ischemic lesions 
of the oculomotor nerves (III, IV and VI), Tolosa Hunt 
syndrome, Raeder’s syndrome, recurrent painful ophthal-
moplegic neuropathy, neuralgia of the superior laryngeal 
nerve, burning mouth syndrome, persistent facial pain, 
temporal arteritis and carotidynia. Although uncommon, 
glossopharyngeal neuralgia is an important consideration 
in the differential diagnosis of OFP.
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Diagnostic approach to OFP
Multiple factors contribute to the diagnostic and ther-
apeutic challenges related to orofacial pain, making a 
multidisciplinary approach essential to the treatment of 
this disorder.  OFP may arise from a variety of tissues in 
the face and head, including the meninges, cornea, dental 
pulp, oral mucosa, nasal mucosa and temporomandibular 
joint. So, the many pathophysiological mechanisms giv-
ing rise to orofacial pain is reflective of the diverse tissue 
types in which it originates. A lack of validated diagnostic 
criteria is one of several obstacles to improving care for 
patients, but also in translational research. Although ef-
forts have been made in the classification of patients with 
temporomandibular joint disorder (41), headache (42) 
and orofacial pain (43), clinical trials indicate that the 
results of pharmacological, electrophysiological and imag-
ing studies have not yet provided sufficient means for the 
comprehensive diagnosis of orofacial pain (44, 45). 
Screening questionnaires, such as the Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS), Neuro-
pathic Pain Diagnostic Questionnaire (DN4), Neuro-
pathic Pain Questionnaire (NPQ) and others, can help 
in the identification of neuropathic pain, but conclusive 
results require assessment of questionnaire findings in 
light of the clinical examination and other diagnostic 
methods. Despite its format, the optimal diagnostic tool 
should distinguish neuropathy from other OFP etiologies. 
Another factor potentially contributing to diagnostic and 
therapeutic failure is insufficient education about pain in 
medical education programs. Anecdotal evidence of such 
a shortcoming was recently confirmed in a study of 242 
medical schools from 15 European countries. The authors 
found that 82% of medical programs do not include a 
separate, compulsory course on pain in the curriculum. 
In schools that do dedicate coursework specifically to the 
study of pain, students only receive an average of 12 elec-
tive or mandatory educational hours on pain manage-
ment, equating to only 0.2% of the overall educational 
program (46). A similar proportion of medical education 
in the United States and Canada is dedicated to the man-
agement of pain conditions (5).
The development and management of analgesic thera-
pies presents another area of future improvement. While 
there has been significant progress in the identification of 
pathophysiological mechanisms underlying acute and 
chronic pain, this knowledge has not led to the develop-
ment of new analgesic or coanalgesics which are more 
efficient, safer or have fewer side effects. In the treatment 
of most chronic neuropathic pain conditions, opioid and 
non-steroidal anti-inflammatory drugs (NSAIDs) remain 
the therapies most frequently  prescribed in clinical prac-
tice (47).  The use of these drugs is very often limited 
because of the risk for abuse of opioids and the gastroin-
testinal, renal and cardiovascular side effects associated 
with NSAIDs (48, 49). Other therapies more specifically 
targeting neuropathic pain are included as the accepted 
standard of care in algorithms published by professional 
organizations. These include tricyclic antidepressants, se-
rotonin reuptake inhibitors (SSRIs), selective serotonin 
norepinephrine reuptake inhibitors (SSNRI), anticonvul-
sants, topical lidocaine, topical capsaicin, intrathecal opi-
oids, corticosteroids and ziconotide. This variety of ther-
apies offers clinicians the potential to utilize drugs whose 
mechanisms of action more specifically targets the par-
ticular pathophysiological processes underlying a given 
pain condition. Most of these therapies act on specific 
neurotransmitters involved in pain pathways, providing 
a sound theoretical basis for their use in the treatment of 
neuropathic and nociceptive pain. Tramadol, for example, 
provides opioid-like activity and also modulates seroto-
nergic and noradrenergic systems. Antidepressants also 
provide pain relief through the modulation of select neu-
rotransmitters while also helping to alleviate symptoms 
of depression, a frequent comorbid condition for those 
suffering from chronic pain. Among the oldest drugs in 
this therapeutic group, tricyclic antidepressants (TCAs) 
appear to modulate pain by potentiating the antinocicep-
tive roles of serotonin and norepinephrine. The activity of 
both of these neurotransmitters has been shown to be 
enhanced by the TCA amitriptyline, the drug most com-
monly used when an antidepressant is included in the 
treatment of chronic pain. The efficacy of newer antide-
pressants varies according to class. While SSRIs have been 
shown to be less effective than TCAs in treating neuro-
pathic pain, SSNRIs are more effective being recom-
mended as the drug of choice in some guidelines (50). If 
medication management fails, then surgical procedures 
may be considered, such as a microvascular decompres-
sion to remove pressure from the trigeminal or glossop-
haryngeal nerve, radiofrequency thermocoagulation, 
gamma knife radiosur gery, or rhizotomy (51, 52).
Potential barriers to proper pain treatment were un-
derscored by the results of a recent study in Croatia. The 
cross-sectional controlled study was conducted on 100 
patients with chronic neuropathic orofacial pain of non-
odontogenic origin. The results confirmed previous find-
ings that pain imparts a significant effect on quality of 
life as measured by standardized parameters (53). The 
study also revealed that the treatment of chronic neuro-
pathic pain is not in accordance with recommendations 
from IASP, European Pain Federation EFIC or The Cro-
atian Pain Society. The study found that 61% of patients 
used NSAIDs and another 34% of patients used the 
weak opioid tramadol alone or in a fixed combination 
with paracetamol. Only 20% of the study participants 
were receiving an anticonvulsant. Medicines from the 
group of strong opioids, tricyclic antidepressants, corti-
costeroids and spasmolytics were not used by any respon-
dent. An insignificant number of patients reported using 
some other treatment, such as acupuncture or biofeed-
back. Some respondents were not receiving any ongoing 
therapies. 
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It can be concluded from this study that the majority 
of neuropathic pain treatments administered in Croatia 
are not in accordance with current guidelines. This may 
be largely explained by administrative restrictions on drug 
prescriptions. Physicians nationwide are largely guided in 
their choice of drug therapy by the extent to which spe-
cific medications are fully covered by the Croatian Health 
Insurance Fund. 
CONCLUSION
The future of orofacial pain treatment depends on the 
development of several key areas. Firstly, further research 
is required to firmly establish a comprehensive, sensitive 
and specific diagnostic classification scheme for all types 
of orofacial pain. This tool should integrate quality of life 
indicators such that they provide additional data on clin-
ical outcomes (54). Additionally, the curriculum of study 
for doctors of both medicine and dentistry should include 
an increased number of educational hours devoted spe-
cifically to the treatment of pain. Finally, health policy 
should be harmonized such that the guidelines for pre-
scribing medications established by insurance providers 
match the most recent evidence-based recommendations 
for the treatment of neuropathic pain.
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